SEC Form 4 · accession 0001209191-18-004659
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas B Neff
Officer — Chief Executive Officer · Director
Period of report
Jan 18, 2018
Accepted (ET)
Jan 19, 2018 · 8:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 18, 2018 | S | 14,658 | $47.56 | D | 2,981,447 | D | |
| Common StockF1,F3 | Jan 18, 2018 | S | 4,242 | $47.92 | D | 2,977,205 | D | |
| Common StockF1,F4 | Jan 18, 2018 | S | 418 | $47.51 | D | 125,424 | I | By Family Partnership |
| Common StockF1,F5 | Jan 19, 2018 | S | 15,200 | $47.18 | D | 2,962,005 | D | |
| Common StockF1,F6 | Jan 19, 2018 | S | 3,700 | $47.68 | D | 2,958,305 | D | |
| Common StockF1,F7 | Jan 19, 2018 | S | 418 | $47.11 | D | 125,006 | I | By Family Partnership |
| Common StockF8 | holding | — | — | — | 60,946 | I | See footnote | |
| Common Stock | holding | — | — | — | 19,500 | I | By Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $46.90 to $47.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $47.90 to $48.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The shares were sold at prices ranging from $47.30 to $47.675. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5The shares were sold at prices ranging from $46.55 to $47.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6The shares were sold at prices ranging from $47.55 to $47.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F7The shares were sold at prices ranging from $46.70 to $47.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F8The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.